Analyst Thomas Shrader of BTIG maintained a Buy rating on Harrow Health, retaining the price target of $63.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight Harrow Health’s promising growth trajectory. The company’s management has outlined a strategic path to achieve significant revenue growth, projecting a $250 million revenue for the fourth quarter of 2027. This projection, although ambitious, is supported by positive feedback from key opinion leaders (KOLs) regarding Harrow’s product lineup, particularly IHEEZO and VEVYE.
IHEEZO, a topical anesthetic, is expected to capture a substantial market share, with KOLs expressing strong enthusiasm for its use in private settings. Similarly, VEVYE is anticipated to dominate its class due to its favorable refill rates and patient reception. Additionally, the relaunch of TRIESENCE and the potential expansion of the MELT franchise into various applications further bolster Harrow’s growth potential. The company’s recent debt restructuring also positions it well for future acquisitions, enhancing its financial flexibility and strategic capabilities.